Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812983 | 0.88 | FBP1 (0.47) | FBP1 | |
| SCHEMBL2814552 | 0.87 | FBP1 (0.46) | FBP1 | |
| SCHEMBL2816512 | 0.85 | FBP1 (0.46) | FBP1 | |
| SCHEMBL2815726 | 0.83 | FBP1 (0.46) | FBP1 | |
| SCHEMBL2817159 | 0.82 | FBP1 (0.48) | FBP1 | |
| SCHEMBL2812272 | 0.81 | NPC1 (0.46) | FBP1 | |
| SCHEMBL2812988 | 0.80 | SMN1; SMN2 (0.45) | FBP1 | |
| SCHEMBL3993827 | 0.79 | FBP1 (0.45) | FBP1 | |
| SCHEMBL3989886 | 0.79 | FBP1 (0.45) | FBP1 | |
| SCHEMBL17957289 | 0.79 | FBP1 (0.44) | FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362057-B2 | Insulin resistance; atherosclerosis; cardiovascular disorders; metabolism disorders | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-01-29 | — | — | US | claimed |
| EP-1910310-B1 | NOVELIMIDAZOLECARBOXAMIDE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2009-06-03 | — | — | EP | claimed |
| US-20080207720-A1 | Novel Imidazolecarboxamide Derivatives as Fructose-1,6-Bisphosphatase Inhibitors, and Pharmaceutical Compositions Comprising Same | MERCK PATENT GESELLSCHAFT (DE) | 2008-08-28 | — | — | US | claimed |
| EP-1910310-A1 | NOVELIMIDAZOLECARBOXAMIDE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007014619-A1 | NOVELIMIDAZOLECARBOXAMIDE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2007-02-08 | — | — | WO | claimed |
| US-8362057-B2 | Insulin resistance; atherosclerosis; cardiovascular disorders; metabolism disorders | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-01-29 | — | — | US | disclosed |
| US-8362057-B2 | Insulin resistance; atherosclerosis; cardiovascular disorders; metabolism disorders | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-01-29 | — | — | US | disclosed |
| EP-1910310-B1 | NOVELIMIDAZOLECARBOXAMIDE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20080207720-A1 | Novel Imidazolecarboxamide Derivatives as Fructose-1,6-Bisphosphatase Inhibitors, and Pharmaceutical Compositions Comprising Same | MERCK PATENT GESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1910310-A1 | NOVELIMIDAZOLECARBOXAMIDE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007014619-A1 | NOVELIMIDAZOLECARBOXAMIDE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207720-A1 | Novel Imidazolecarboxamide Derivatives as Fructose-1,6-Bisphosphatase Inhibitors, and Pharmaceutical Compositions Comprising Same | FBP1, INSR, GPR119 | FBP1 1/4885SOAT1 1702/4885LPAR1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.